Valbenazine adverse effects: which is reported to occur at >10% frequency?

Valbenazine adverse effects: which is reported to occur at >10% frequency?

• A. Nausea
• B. Akathisia
• C. QT prolongation
• D. Somnolence

Answer: (D)

The main idea here is understanding which adverse effects occur most frequently with valbenazine. In clinical data, somnolence stands out as the adverse effect reported in more than 10% of patients. This reflects the drug’s central nervous system–depressant effects, which can lead to daytime sleepiness or fatigue. The other options—nausea, akathisia, and QT prolongation—appear less commonly with valbenazine. Nausea can occur but usually at lower frequencies; akathisia is not a dominant side effect for VMAT2 inhibitors, and QT prolongation is not a prominent or consistent issue with valbenazine. Thus, somnolence is the most common adverse effect, occurring above the 10% threshold.

The main idea here is understanding which adverse effects occur most frequently with valbenazine. In clinical data, somnolence stands out as the adverse effect reported in more than 10% of patients. This reflects the drug’s central nervous system–depressant effects, which can lead to daytime sleepiness or fatigue. The other options—nausea, akathisia, and QT prolongation—appear less commonly with valbenazine. Nausea can occur but usually at lower frequencies; akathisia is not a dominant side effect for VMAT2 inhibitors, and QT prolongation is not a prominent or consistent issue with valbenazine. Thus, somnolence is the most common adverse effect, occurring above the 10% threshold.